Esperion Therapeutics Inc. (ESPR)

78.90
NASDAQ : Health Technology
Prev Close 77.94
Day Low/High 77.11 / 79.68
52 Wk Low/High 20.39 / 82.18
Avg Volume 571.20K
Exchange NASDAQ
Shares Outstanding 26.50M
Market Cap 2.01B
EPS -7.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

First Week of September 21st Options Trading For Esperion Therapeutics (ESPR)

Investors in Esperion Therapeutics Inc saw new options begin trading this week, for the September 21st expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 231 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

ESPR Crosses Above Average Analyst Target

In recent trading, shares of Esperion Therapeutics Inc have crossed above the average analyst 12-month target price of $74.44, changing hands for $75.84/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Notable Thursday Option Activity: ESPR, EXPR, LULU

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Esperion Therapeutics Inc , where a total of 3,150 contracts have traded so far, representing approximately 315,000 underlying shares. That amounts to about 56.5% of ESPR's average daily trading volume over the past month of 557,890 shares.

Delta Air Lines, BioTelemetry, TransUnion: 'Mad Money' Lightning Round

Delta Air Lines, BioTelemetry, TransUnion: 'Mad Money' Lightning Round

Jim Cramer is bullish on Delta Air Lines, BioTelemetry, TransUnion, Amgen and Littelfuse.

Are Stocks Cheaper Than We Think?: Cramer's 'Mad Money' Recap (Tues 10/17/17)

Are Stocks Cheaper Than We Think?: Cramer's 'Mad Money' Recap (Tues 10/17/17)

Jim Cramer says there's a case to be made for underpricing, even in this market.

Markets Focus on Business: Cramer's 'Mad Money' Recap (Monday 8/28/17 )

Markets Focus on Business: Cramer's 'Mad Money' Recap (Monday 8/28/17 )

Jim Cramer says people care about natural disasters, but the markets are moved by data points, such as Apple's iPhone news.

Short Interest Declines 10% For ESPR

Short Interest Declines 10% For ESPR

The most recent short interest data has been released for the 08/15/2017 settlement date, which shows a 546,557 share decrease in total short interest for Esperion Therapeutics Inc , to 4,907,536, a decrease of 10.02% since 07/31/2017. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Steady Climb Amid Low Volume

Bulls should curb their enthusiasm.

These Are the Best Growth Stocks Right Now in Biotech

These Are the Best Growth Stocks Right Now in Biotech

Top names.

Jobs Report Puts Stocks to Work

Next week's focus will be on earnings.

Biotech Movers: Akebia Shares Down After Pricing Stock Offering

Biotech Movers: Akebia Shares Down After Pricing Stock Offering

Akebia Therapeutics, Sarepta Therapeutics and Esperion Therapeutics were among the biotech stock movers in premarket trading on June 29.